Vol.37, 2024 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报

2024-12-16

1. Summary of the Week

From December 7 to 13, 2024, the global pharmaceutical market saw the signing of 21 asset licensing and collaboration agreements. The China Biotech Industry accounted for eight of these deals, including 3 out-licensing transactions, 1 in-licensing transaction, and 4 domestic agreements.

The standout out-licensing transaction was Mabwell’s strategic collaboration with TABUK for two biosimilars targeting the Middle East and North Africa regions. The sole in-licensing transaction of the week involved King-Friend acquiring global rights (excluding Greater China) for XENLETA® from Nabriva Therapeutics. Among domestic deals, the most notable was CSPC Pharmaceutical Group licensing global rights for its MAT2A inhibitor SYH2039 to BeOne. This agreement included an upfront payment of $150 million and a total deal value of $1.835 billion.

Internationally, 13 asset licensing and collaboration agreements were signed during the week. The largest of these was a partnership between Relation Therapeutics and GSK to explore multiple new targets in the areas of fibrosis and osteoarthritis. This deal included an upfront payment of $30 million and a total value of $508 million.

2024年12月7日-13日，全球医药市场共签署了21项资产授权和合作协议。中国市场共达成8项，包括3项出海交易、1项引进交易和4项国内交易。

本周中国市场值得关注的出海交易是迈威生物与 TABUK 就两款生物类似药在中东和北非地区达成战略合作。本周唯一的引进交易是健友股份从Nabriva Therapeutics获得XENLETA®大中华区以外的全球权益。本周最引人注目的国内交易是石药集团授权给百济神州MAT2A抑制剂SYH2039的全球权益，首付款1.5亿美元，总价值18.35亿美元。

国际市场上，共签署了13项资产授权和合作协议。最大的一笔交易是Relation Therapeutics与GSK达成合作，共同探索纤维化和骨关节炎领域的多个新靶点，首付款3000万美元，总价值5.08亿美元。

2. Licensing Deals

2a. China section

2b. Global section

3. Top Deals of the year 2024

4. 2019-2023 China Innovative Drug Licensing Transactions

About YAFO Capital

Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with a professional team in our China, U.S., EU, and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions. For more information, please visit http://www.yafocapital.com

雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。

ACCESS CHINA